70298-88-3

Usage

Uses

Used in Pharmaceutical Industry:
2,2-DIMETHYL-N-PYRIDIN-3-YL-PROPIONAMIDE is used as a pharmaceutical intermediate for the synthesis of various biologically active compounds. It serves as a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Research and Development:
In the fields of medicinal chemistry, organic synthesis, and drug discovery, 2,2-DIMETHYL-N-PYRIDIN-3-YL-PROPIONAMIDE is utilized for its potential applications in the treatment of certain diseases and disorders. Its unique structure and properties make it a valuable tool for exploring new therapeutic avenues and enhancing our understanding of molecular interactions in biological systems.

InChI:InChI=1/C10H14N2O/c1-10(2,3)9(13)12-8-5-4-6-11-7-8/h4-7H,1-3H3,(H,12,13)

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 3282-30-2 pivaloyl chloride 
• 75-98-9 Trimethylacetic acid 
• 75-84-3 2,2-dimethyl-propanol-1 
• 754-10-9 2,2-dimethylpropionamide 

Downstream Products

• 82791-71-7 N-[4-(Hydroxy-p-tolyl-methyl)-pyridin-3-yl]-2,2-dimethyl-propionamide 
• 125867-18-7 N-[4-(Hydroxy-diphenyl-methyl)-pyridin-3-yl]-2,2-dimethyl-propionamide 
• 86847-91-8 3-<(2,2-Dimethyl-1-oxopropyl)amino>-4-pyridinecarboxylic Acid 
• 112175-38-9 N-(4-benzoylpyridin-3-yl)-2,2-dimethylpropionamide 
• 82791-70-6 2,2-Dimethyl-N-<4-(hydroxyphenylmethyl)-3-pyridinyl>propanamide 
• 125867-17-6 (2,4-dichlorophenyl)(3-pivaloylamino-4-pyridyl)methanol 
• 127446-35-9 2,2-Dimethyl-N-(4-formyl-3-pyridinyl)propanamide 
• 82791-72-8 (2-methoxyphenyl)(3-pivaloylamino-4-pyridyl)methanol 
• 113975-32-9 2,2-dimethyl-N-(4-iodo-3-pyridinyl)propanamide 
• 1006379-86-7 N-(4-{hydroxy[4-(trifluoromethyl)phenyl]methyl}pyridin-3-yl)-2,2-dimethylpropanamide 
• 131653-64-0 2,2-dimethyl-N-(4-phenyl-3-pyridyl)propanamide 
• 131653-65-1 2,2-dimethyl-N-(4-(2-methoxyphenyl)-3-pyridyl)propanamide 
• 131653-66-2 2-[3-(2,2-dimethylpropanoylamino)pyridin-4-yl]-N,N-diisopropylbenzamide 
• 131653-67-3 Diethyl-carbamic acid 2-[3-(2,2-dimethyl-propionylamino)-pyridin-4-yl]-phenyl ester 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase

We pursued a structure-guided approach toward the development of improved dihydroorotate dehydrogenase (DHODH) inhibitors with the goal of forming new interactions between DHODH and the brequinar class of inhibitors. Two potential residues, T63 and Y356, suitable for novel H-bonding interactions, were identified in the brequinar-binding pocket. Analogues were designed to maintain the essential pharmacophore and form new electrostatic interactions through strategically positioned H-bond accepting groups. This effort led to the discovery of potent quinoline-based analogues 41 (DHODH IC50 = 9.71 ± 1.4 nM) and 43 (DHODH IC50 = 26.2 ± 1.8 nM). A cocrystal structure between 43 and DHODH depicts a novel water mediated H-bond interaction with T63. Additional optimization led to the 1,7-naphthyridine 46 (DHODH IC50 = 28.3 ± 3.3 nM) that forms a novel H-bond with Y356. Importantly, compound 41 possesses significant oral bioavailability (F = 56%) and an elimination t1/2 = 2.78 h (PO dosing). In conclusion, the data supports further preclinical studies of our lead compounds toward selection of a candidate for early-stage clinical development.

Quinolinones as Inhibitors of Translation Initiation Complex

Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

Preparation technology for 1-(3-amino-4-pyridyl) aceton

The invention discloses a preparation technology for 1-(3-amino-4-pyridyl) aceton. The preparation technology is characterized by comprising the following steps: (1) by taking 3-aminopyridine as a raw material, participating into amidation reaction, thereby generating 3-teramidyl pyridine; (2) generating N-(4-aceton pyridine-3-group) trimethyl acetamide through the substitution reaction of the 3-teramidyl pyridine; and (3) hydrolyzing the N-(4-aceton pyridine-3-group) trimethyl acetamide, thereby acquiring the target product 1-(3-amino-4-pyridyl) aceton. The raw materials in process route are low in cost and easily acquired, the operation condition is mild and easily controlled and the preparation technology is beneficial to the industrial application.

Rhodium-Catalyzed oxidative amidation of sterically hindered aldehydes and alcohols

A rhodium-catalyzed oxidative amidation reaction has been developed with sterically hindered aldehydes and alcohols for the synthesis of amides containing a quaternary carbon at the α position. A variety of amine nucleophiles, both aliphatic and aromatic, are employed and afford the corresponding amides in good to excellent yields. Finally, mechanistic studies are performed to gain insight into both catalytic cycles.

Amine Activation: Synthesis of N-(Hetero)arylamides from Isothioureas and Carboxylic Acids

A novel method for N-(hetero)arylamide synthesis based on rarely explored amine activation, rather than classical acid activation, is reported. The activated amines are easily prepared using a three-component reaction with commercial reagents. The new method shows a broad scope including challenging amides not (efficiently) accessible via classical protocols.

PROTEIN KINASE INHIBITORS

The present invention provides a compound incorporating a group of formula (I) wherein: 1 of X, Y and Z is nitrogen and the other 2 are carbon; V is sulpur or carbon; R3 is oxygen or fluorine; R4 is an optionally present C1-3 alkyl group optionally substituted by fluorine; R5 is an optionally present cyclic group with 5-7 heavy atoms in the ring which may be carbocyclic or heterocyclic and aromatic or aliphatic and is optionally substituted, e.g. by a halogen, C1-2 alkyl or fluoroalkyl, OH, OR6, cyano, COOR6, CONHR6, sulfonamide or NHR6, in which R6 is a C1-2 alkyl or fluoroalkyl; at least one of R4 and R5 is present and R4 and R5 may both be present; m and n are each 1 or 2 depending on the identity of V and R3; when n=2 each R3 may be the same or different but are preferably the same, when m=2, each R4 and each R5 may be the same or different but are preferably the same; and W represents hydrogen, carbon, nitrogen, oxygen or sulphur; or incorporating a salt, hydrate or solvate of a group of formula (I); as well as therapeutic uses of these compounds, in particular as inhibitors of protein kinase activity and in the treatment of inflammation, inflammatory conditions and cancer.

CuCl-catalyzed ortho trifluoromethylation of arenes and heteroarenes with a pivalamido directing group

The CuCl catalyzed direct trifluoromethylation of sp2 C-H bonds has been realized, using the Togni reagent as the CF3 source. This reaction achieves the goal of regio-selectively converting C-H into C-CF 3 with ecological and readily available starting materials.

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS

This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS

This invention relates to novel 3-aminopyridines of the formula (I) wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.